SBM:CA:CDX-Sirona Biochem Corp (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 0.085

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.18M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sirona Biochem Corp is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.19B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.08B
MIR:CA MedMira Inc

N/A

USD 0.06B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.67M

ETFs Containing SBM:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.17% 12% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.17% 12% F 30% F
Trailing 12 Months  
Capital Gain -10.53% 19% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.53% 19% F 47% F
Trailing 5 Years  
Capital Gain -83.00% 8% B- 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.00% 8% B- 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -27.48% N/A N/A 10% F
Dividend Return -27.48% N/A N/A 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.05% N/A N/A 87% B+
Risk Adjusted Return -109.69% N/A N/A 6% D-
Market Capitalization 0.03B 56% F 65% D

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector